Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    1739240 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Condition: Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions: Drug: Rituximab;   Other: Placebo
2 Unknown  Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Conditions: Wegener's Granulomatosis;   Churg-Strauss Syndrome;   Microscopic Polyangiitis;   Polyarteritis Nodosa
Interventions: Drug: Methotrexate;   Drug: Cyclophosphamide
3 Completed An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
Condition: Wegener's Granulomatosis
Intervention: Drug: Rituximab
4 Completed Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Mycophenolate Mofetil
5 Completed Etanercept to Treat Wegener's Granulomatosis
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Etanercept
6 Completed Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Interleukin-10
7 Completed Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention:
8 Completed Treatment of Wegener's Granulomatosis With Cyclophosphamide
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: cyclophosphamide

Indicates status has not been verified in more than two years